RPRX logo

RPRX Royalty Pharma plc

NASDAQ · Medical - Pharmaceuticals · Healthcare

$68.45
+0.73 (+1.08%)

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabet…

Market Cap: $30.48Bwww.royaltypharma.com

Price

No data yet.

Social Signal Score

53
5d
50
1 mentions
—
30d
54
14 mentions
—
60d
53
21 mentions
—
90d
54
32 mentions
—
news: 19 · rss: 11 · podcast: 1 · marketaux: 1

Analyst Ratings

11 analysts
Buyconsensus
Strong Buy 0Buy 11Hold 0Sell 0Strong Sell 0
Avg price target$71+3.7%
Low $66Median $67High $80
Current Consensus

Revenue

$690.10M+58.69%
$434.88M$519.96M$605.03M$690.10M
Mar 2019Sep 2026

Analyst Estimates

FY2025
$4.63
$4.28–$4.76
5 analysts
FY2026
$5.39+16% YoY
$5.34–$5.44
4 analysts
FY2027
$5.86+9% YoY
$5.68–$5.99
4 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Pablo Legorreta
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Employees
100
Beta
0.41
Country
US
Piotroski score
6 / 9 (Middling)
Altman Z-score
2.47
www.royaltypharma.com